Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment

被引:15
|
作者
Quan, H [1 ]
Luo, XH [1 ]
Capizzi, T [1 ]
机构
[1] Merck & Co Inc, Res Labs, Clin Biostat & Res Decis Sci, Rahway, NJ 07065 USA
关键词
closed procedure; family-wise error rate; strong control; weak control; adjusted p-value;
D O I
10.1002/sim.2101
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Frequently, multiple doses of an active treatment and multiple endpoints are simultaneously considered in the designs of clinical trials. For these trials, traditional multiplicity adjustment procedures such as Bonferroni, Hochberg and Hommel procedures can be applied when treating the comparisons of different doses to the control on all endpoints at the same level. However, these approaches will not take into account the possible dose-response relationship on each endpoint, and therefore are less specific and may have lower power. To gain power, in this paper, we consider the problem as a two-dimensional multiplicity problem: one dimension concerns the multiple doses and the other dimension concerns the multiple endpoints. We propose procedures which consider the dose order to form the closure of the procedures and control the family-wise type I error rate in a strong sense. For this two-dimensional problem, numerical examples show that procedures proposed in this paper in general have higher power than the commonly used procedures (e.g. the regular Hochberg procedure) especially for comparing the higher dose to the control. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:2151 / 2170
页数:20
相关论文
共 50 条
  • [21] THE USE OF RANDOMIZATION TESTS FOR MULTIPLE ENDPOINTS IN CLINICAL-TRIALS
    KARRISON, T
    CONTROLLED CLINICAL TRIALS, 1985, 6 (03): : 240 - 241
  • [22] Some remaining challenges regarding multiple endpoints in clinical trials
    Snapinn, Steven
    STATISTICS IN MEDICINE, 2017, 36 (28) : 4441 - 4445
  • [23] One-sided tests in clinical trials with multiple endpoints
    Bloch, DA
    Lai, TL
    Tubert-Bitter, P
    BIOMETRICS, 2001, 57 (04) : 1039 - 1047
  • [24] Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
    Sakamaki, Kentaro
    Yoshida, Seitaro
    Morita, Yusuke
    Kamiura, Toshifumi
    Iba, Katsuhiro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (03) : 528 - 533
  • [25] Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan
    Kentaro Sakamaki
    Seitaro Yoshida
    Yusuke Morita
    Toshifumi Kamiura
    Katsuhiro Iba
    Naoyuki Ogawa
    Hideki Suganami
    Satoru Tsuchiya
    Satoru Fukimbara
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 528 - 533
  • [26] Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials
    Wiens, Brian L.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (01) : 52 - 62
  • [27] Consistency Based Multiplicity Adjustment Approach-Multiple Doses in Phase III Studies
    Li, Qian H.
    Deng, Qiqi
    Ting, Naitee
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (04): : 748 - 754
  • [28] Finding Multiple Signals in the Noise: Handling Multiplicity in Clinical Trials
    Chowdhry, Amit K.
    Park, John
    Kang, John
    Sakthivel, Gukan
    Pugh, Stephanie
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (03): : 750 - 755
  • [29] Advanced multiplicity adjustment methods in clinical trials
    Alosh, Mohamed
    Bretz, Frank
    Huque, Mohammad
    STATISTICS IN MEDICINE, 2014, 33 (04) : 693 - 713
  • [30] Practical guidelines for multiplicity adjustment in clinical trials
    Proschan, MA
    Waclawiw, MA
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 527 - 539